Archer Daniels Midland (ADM)

Total Liabilities

$29.66B

Quarterly · Period ending: · USD

ADM logo

ADM Total Liabilities

Latest reported$29.66B
ADM Quarterly Total Liabilities ($1.24B → $29.66B)
High-resolution chart · PNG

ADM total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Archer Daniels Midland Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
29,655,000,000
32,495,000,000
29,362,000,000
29,166,000,000
29,309,000,000
31,020,000,000
30,840,000,000
29,932,000,000
30,237,000,000
31,292,000,000
30,166,000,000
29,512,000,000
30,220,000,000
33,605,000,000
35,158,000,000
33,985,000,000
37,141,000,000
40,849,000,000
33,369,000,000
30,083,000,000
29,284,000,000
30,535,000,000
29,623,000,000
25,369,000,000
24,945,000,000
29,348,000,000
24,714,000,000
22,856,000,000
23,584,000,000
24,192,000,000
21,788,000,000
20,618,000,000
19,990,000,000
22,304,000,000
21,588,000,000
21,339,000,000
20,372,000,000
22,475,000,000
22,564,000,000
22,257,000,000
22,388,000,000
21,768,000,000
22,242,000,000
22,999,000,000
22,010,000,000
22,958,000,000
24,367,000,000
21,560,000,000
19,711,000,000
21,382,000,000
23,558,000,000
21,882,000,000
21,225,000,000
24,250,000,000
26,319,000,000
23,602,000,000
23,307,000,000
23,351,000,000
23,039,000,000
23,514,000,000
27,083,000,000
26,706,000,000
20,649,000,000
17,177,000,000
17,557,000,000
18,734,000,000
17,618,000,000
17,929,000,000
18,548,000,000
20,207,000,000
21,174,000,000
23,566,000,000
23,351,000,000
21,166,000,000
17,572,000,000
13,865,000,000
14,672,067,000
14,272,930,000
11,682,275,000
11,462,150,000
11,371,083,000
11,233,356,000
11,202,345,000
10,165,000,000
10,408,691,000
10,844,527,000
10,989,927,000
11,670,605,000
13,228,473,000
12,332,748,000
10,469,360,000
10,113,682,000
10,698,025,000
11,026,051,000
10,153,769,000
8,661,452,000
8,823,940,000
8,733,821,000
8,155,347,000
8,008,248,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.